New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and clinical research affiliate, Lupus Therapeutics, broadened a collaboration with Bristol-Myers Squibb (BMS) to study the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN) – kidney damage affecting about 50 percent of people with lupus. This expands the existing collaboration in systemic lupus erythematosus (SLE).
BMS-986165 selectively inhibits the action of tyrosine kinase 2 (TYK2), an enzyme involved in many autoimmune diseases, including lupus and lupus nephritis.
The full press release is available on the Lupus Therapeutics website.
